Furthermore, increased expression of p53 signaling pathway target genes were identified following combination treatment with HDM201 and GSK2830371, suggesting potential roles for this combination strategy in iCCA therapy. The gene discussed is TP53; the disease is infantile convulsions and choreoathetosis.